AMGN—

$0.00

BIIB—

$0.00

GILD—

$0.00

REGN—

$0.00

VRTX—

$0.00

MRNA—

$0.00

BNTX—

$0.00

ILMN—

$0.00

SNY—

$0.00

VTRS—

$0.00

ALNY—

$0.00

ARGX—

$0.00

BMRN—

$0.00

ACAD—

$0.00

ALKS—

$0.00

EXEL—

$0.00

HALO—

$0.00

INCY—

$0.00

INSM—

$0.00

IONS—

$0.00

JAZZ—

$0.00

NBIX—

$0.00

NVAX—

$0.00

NVCR—

$0.00

PTCT—

$0.00

RARE—

$0.00

RPRX—

$0.00

SRPT—

$0.00

UTHR—

$0.00

PACB—

$0.00

BBIO—

$0.00

ARVN—

$0.00

BEAM—

$0.00

CRSP—

$0.00

EDIT—

$0.00

NTLA—

$0.00

RXRX—

$0.00

SMMT—

$0.00

MDGL—

$0.00

AXSM—

$0.00

AUPH—

$0.00

ADPT—

$0.00

AGIO—

$0.00

ALLO—

$0.00

ARCT—

$0.00

ARWR—

$0.00

BCRX—

$0.00

CYTK—

$0.00

DNLI—

$0.00

ENTA—

$0.00

ERAS—

$0.00

FTRE—

$0.00

GMAB—

$0.00

GERN—

$0.00

GRFS—

$0.00

GH—

$0.00

IDYA—

$0.00

IMCR—

$0.00

IMVT—

$0.00

IOVA—

$0.00

JANX—

$0.00

KYMR—

$0.00

KRYS—

$0.00

KNSA—

$0.00

LENZ—

$0.00

LGND—

$0.00

LYEL—

$0.00

MEDP—

$0.00

MIRM—

$0.00

NGNE—

$0.00

ORIC—

$0.00

PCRX—

$0.00

PRAX—

$0.00

PTGX—

$0.00

RVMD—

$0.00

RYTM—

$0.00

RCKT—

$0.00

ROIV—

$0.00

SANA—

$0.00

SRRK—

$0.00

SIGA—

$0.00

STOK—

$0.00

GPCR—

$0.00

SUPN—

$0.00

TARS—

$0.00

TSHA—

$0.00

TVTX—

$0.00

TYRA—

$0.00

QURE—

$0.00

VERA—

$0.00

VCEL—

$0.00

VIR—

$0.00

WVE—

$0.00

XNCR—

$0.00

XENE—

$0.00

ZLAB—

$0.00

ZYME—

$0.00

KROS—

$0.00

REPL—

$0.00

RGNX—

$0.00

SPRY—

$0.00

ADMA—

$0.00

AMLX—

$0.00

AMPH—

$0.00

ASND—

$0.00

SEPN—

$0.00

TBPH—

$0.00

TRVI—

$0.00

HRMY—

$0.00

PCVX—

$0.00

MNKD—

$0.00

AMGN—

$0.00

BIIB—

$0.00

GILD—

$0.00

REGN—

$0.00

VRTX—

$0.00

MRNA—

$0.00

BNTX—

$0.00

ILMN—

$0.00

SNY—

$0.00

VTRS—

$0.00

ALNY—

$0.00

ARGX—

$0.00

BMRN—

$0.00

ACAD—

$0.00

ALKS—

$0.00

EXEL—

$0.00

HALO—

$0.00

INCY—

$0.00

INSM—

$0.00

IONS—

$0.00

JAZZ—

$0.00

NBIX—

$0.00

NVAX—

$0.00

NVCR—

$0.00

PTCT—

$0.00

RARE—

$0.00

RPRX—

$0.00

SRPT—

$0.00

UTHR—

$0.00

PACB—

$0.00

BBIO—

$0.00

ARVN—

$0.00

BEAM—

$0.00

CRSP—

$0.00

EDIT—

$0.00

NTLA—

$0.00

RXRX—

$0.00

SMMT—

$0.00

MDGL—

$0.00

AXSM—

$0.00

AUPH—

$0.00

ADPT—

$0.00

AGIO—

$0.00

ALLO—

$0.00

ARCT—

$0.00

ARWR—

$0.00

BCRX—

$0.00

CYTK—

$0.00

DNLI—

$0.00

ENTA—

$0.00

ERAS—

$0.00

FTRE—

$0.00

GMAB—

$0.00

GERN—

$0.00

GRFS—

$0.00

GH—

$0.00

IDYA—

$0.00

IMCR—

$0.00

IMVT—

$0.00

IOVA—

$0.00

JANX—

$0.00

KYMR—

$0.00

KRYS—

$0.00

KNSA—

$0.00

LENZ—

$0.00

LGND—

$0.00

LYEL—

$0.00

MEDP—

$0.00

MIRM—

$0.00

NGNE—

$0.00

ORIC—

$0.00

PCRX—

$0.00

PRAX—

$0.00

PTGX—

$0.00

RVMD—

$0.00

RYTM—

$0.00

RCKT—

$0.00

ROIV—

$0.00

SANA—

$0.00

SRRK—

$0.00

SIGA—

$0.00

STOK—

$0.00

GPCR—

$0.00

SUPN—

$0.00

TARS—

$0.00

TSHA—

$0.00

TVTX—

$0.00

TYRA—

$0.00

QURE—

$0.00

VERA—

$0.00

VCEL—

$0.00

VIR—

$0.00

WVE—

$0.00

XNCR—

$0.00

XENE—

$0.00

ZLAB—

$0.00

ZYME—

$0.00

KROS—

$0.00

REPL—

$0.00

RGNX—

$0.00

SPRY—

$0.00

ADMA—

$0.00

AMLX—

$0.00

AMPH—

$0.00

ASND—

$0.00

SEPN—

$0.00

TBPH—

$0.00

TRVI—

$0.00

HRMY—

$0.00

PCVX—

$0.00

MNKD—

$0.00

Commentary

Analysis of capital markets, strategy and investor sentiment across biotech and pharma.

All Commentary Equities Policy Geopolitics

GSK (GSK) ends an early hepatitis B trial as pipeline choices narrow

GSK (GSK) ends an early hepatitis B trial as pipeline choices narrow

Editorial Team21 October 2026 · 3 min

Ambrose Healthcare and AM-Pharma (both private): €161m deal backs a rare-disease pivot

Ambrose Healthcare and AM-Pharma (both private): €161m deal backs a rare-disease pivot

Editorial Team20 October 2026 · 3 min

AstraZeneca (AZN) and Oracle (ORCL) target the trial-recruitment bottleneck

AstraZeneca (AZN) and Oracle (ORCL) target the trial-recruitment bottleneck

Editorial Team20 October 2026 · 3 min

Johnson & Johnson (JNJ) strengthens Tremfya’s long-term Crohn’s evidence

Johnson & Johnson (JNJ) strengthens Tremfya’s long-term Crohn’s evidence

Editorial Team19 October 2026 · 3 min

Perceive Biotherapeutics (Private) Completes Enrolment in Geographic Atrophy Gene-Therapy Study

Perceive Biotherapeutics (Private) Completes Enrolment in Geographic Atrophy Gene-Therapy Study

Editorial Team12 October 2026 · 3 min

Sling Therapeutics (Private) Reports Durability Follow-Up for Oral Thyroid Eye Disease Drug

Sling Therapeutics (Private) Reports Durability Follow-Up for Oral Thyroid Eye Disease Drug

Editorial Team12 October 2026 · 3 min

Arcutis Biotherapeutics (NASDAQ: ARQT) Reports Treatment-Control Concerns in Dermatology Survey

Arcutis Biotherapeutics (NASDAQ: ARQT) Reports Treatment-Control Concerns in Dermatology Survey

Editorial Team11 October 2026 · 3 min

MannKind (NASDAQ: MNKD) Adds Furoscix ReadyFlow Data at Heart Failure Meeting

MannKind (NASDAQ: MNKD) Adds Furoscix ReadyFlow Data at Heart Failure Meeting

Editorial Team11 October 2026 · 3 min

Seaport Therapeutics (NASDAQ: SPTX) and PureTech Health (LSE: PRTC) Detail GlyphAgo Exposure Data

Seaport Therapeutics (NASDAQ: SPTX) and PureTech Health (LSE: PRTC) Detail GlyphAgo Exposure Data

Editorial Team11 October 2026 · 3 min

Revolution Medicines (NASDAQ: RVMD) Faces Fresh Scrutiny of Rasonque Subgroup Data

Revolution Medicines (NASDAQ: RVMD) Faces Fresh Scrutiny of Rasonque Subgroup Data

Editorial Team10 October 2026 · 3 min

GSK (LSE: GSK) Expands Chai Discovery Partnership After Laboratory Evaluation

GSK (LSE: GSK) Expands Chai Discovery Partnership After Laboratory Evaluation

Editorial Team10 October 2026 · 3 min

Endeavor BioMedicines (Private) Reports Phase 2b Lung Fibrosis Win for Taladegib

Endeavor BioMedicines (Private) Reports Phase 2b Lung Fibrosis Win for Taladegib

Editorial Team8 October 2026 · 3 min

Guardant Health (NASDAQ: GH) Adds Melanoma Evidence for Reveal Blood Test

Guardant Health (NASDAQ: GH) Adds Melanoma Evidence for Reveal Blood Test

Editorial Team6 October 2026 · 3 min

Zag Bio (Private) Moves Type 1 Diabetes Candidate ZAG-101 Into Clinical Development

Zag Bio (Private) Moves Type 1 Diabetes Candidate ZAG-101 Into Clinical Development

Editorial Team5 October 2026 · 3 min

Adecto Pharmaceuticals (Private) Closes After Funding Runway Expires

Adecto Pharmaceuticals (Private) Closes After Funding Runway Expires

Editorial Team4 October 2026 · 3 min

Xaira Therapeutics (Private) Reveals Its Antibody-Design Platform

Xaira Therapeutics (Private) Reveals Its Antibody-Design Platform

Editorial Team4 October 2026 · 3 min

Century Therapeutics (Nasdaq: IPSC) Presents Preclinical Islet-Replacement Data

Century Therapeutics (Nasdaq: IPSC) Presents Preclinical Islet-Replacement Data

Editorial Team2 October 2026 · 3 min

Lutris Pharma (Private) Reports Updated Results for Cancer-Treatment Rash

Lutris Pharma (Private) Reports Updated Results for Cancer-Treatment Rash

Editorial Team1 October 2026 · 3 min

TriGemX Bio (Private) Raises $94 Million for Phase III Migraine Development

TriGemX Bio (Private) Raises $94 Million for Phase III Migraine Development

Editorial Team1 October 2026 · 3 min

Bicara Therapeutics (Nasdaq: BCAX) Prepares a Leadership Handover

Bicara Therapeutics (Nasdaq: BCAX) Prepares a Leadership Handover

Editorial Team1 October 2026 · 3 min

Organon (NYSE: OGN) Takes a Different Creative Route for Vtama

Organon (NYSE: OGN) Takes a Different Creative Route for Vtama

Editorial Team1 October 2026 · 3 min

Varda Space Industries (Private) Raises $251 Million for Orbital Manufacturing

Varda Space Industries (Private) Raises $251 Million for Orbital Manufacturing

Editorial Team30 September 2026 · 3 min

Novo and Lilly's Latest Comparisons Need Careful Reading

Novo and Lilly's Latest Comparisons Need Careful Reading

Editorial Team29 September 2026 · 3 min

Roche's Muscle-Sparing Setback Raises the Bar for Obesity Add-Ons

Roche's Muscle-Sparing Setback Raises the Bar for Obesity Add-Ons

Editorial Team28 September 2026 · 3 min

Merck's HIV Campaign Looks Beyond Medication

Merck's HIV Campaign Looks Beyond Medication

Editorial Team28 September 2026 · 3 min

Pandemic Manufacturing Capacity Needs a Business Model Between Crises

Pandemic Manufacturing Capacity Needs a Business Model Between Crises

Editorial Team27 September 2026 · 3 min

Oral Obesity Prescriptions Rebound, but Revenue Remains a Separate Test

Oral Obesity Prescriptions Rebound, but Revenue Remains a Separate Test

Editorial Team26 September 2026 · 3 min

Roche Proposes Former Takeda Chief for Its Board

Roche Proposes Former Takeda Chief for Its Board

Editorial Team23 September 2026 · 3 min

Anthropic and OpenEvidence Plan Wider Access to Medical AI

Anthropic and OpenEvidence Plan Wider Access to Medical AI

Editorial Team23 September 2026 · 3 min

Pharma's Factory Expansion Runs Into a Talent Question

Pharma's Factory Expansion Runs Into a Talent Question

Editorial Team23 September 2026 · 3 min

Novo's 13,000-Person Workforce Decline Is Not a New Layoff Round

Novo's 13,000-Person Workforce Decline Is Not a New Layoff Round

Editorial Team22 September 2026 · 3 min

Viking's Maintenance Data Address Life After Initial Weight Loss

Viking's Maintenance Data Address Life After Initial Weight Loss

Editorial Team22 September 2026 · 3 min

Boehringer's Envisagenics Pact Puts RNA Splicing on the Deal Agenda

Boehringer's Envisagenics Pact Puts RNA Splicing on the Deal Agenda

Editorial Team22 September 2026 · 3 min

Anthropic Moves Biology AI Beyond the Computer Screen

Anthropic Moves Biology AI Beyond the Computer Screen

Editorial Team19 September 2026 · 3 min

Biopharma Hiring Recovers Unevenly Across the US

Biopharma Hiring Recovers Unevenly Across the US

Editorial Team18 September 2026 · 4 min

Genentech Uses Humour to Make Diabetic Eye Disease Discussable

Genentech Uses Humour to Make Diabetic Eye Disease Discussable

Editorial Team18 September 2026 · 4 min

Lilly Takes Alzheimer's Awareness Beyond Advertising With a Fresh-Produce Initiative

Lilly Takes Alzheimer's Awareness Beyond Advertising With a Fresh-Produce Initiative

Editorial Team18 September 2026 · 4 min

Goa Therapeutics Launches With a Broad Consumer Vision Resting on a Narrow First Study

Goa Therapeutics Launches With a Broad Consumer Vision Resting on a Narrow First Study

Editorial Team18 September 2026 · 4 min

Biotech's AI Hiring Challenge Goes Beyond Salary Competition With Tech

Biotech's AI Hiring Challenge Goes Beyond Salary Competition With Tech

Editorial Team16 September 2026 · 4 min

Royalty Pharma's $7.5 Million Donation Tests the Logic of Philanthropic Capital in Drug Discovery

Royalty Pharma's $7.5 Million Donation Tests the Logic of Philanthropic Capital in Drug Discovery

Editorial Team15 September 2026 · 4 min

Blood Centres Make a Case for a Bigger Role in Cell Therapy

Blood Centres Make a Case for a Bigger Role in Cell Therapy

Editorial Team15 September 2026 · 4 min

Novo Drops Nordisk From Its Branding as Competition Intensifies

Novo Drops Nordisk From Its Branding as Competition Intensifies

Editorial Team14 September 2026 · 4 min

Cancer Vaccines Face a Commercial Choice Between Personalisation and Scale

Cancer Vaccines Face a Commercial Choice Between Personalisation and Scale

Editorial Team14 September 2026 · 4 min

Enhertu's Lung Cancer Results Put the Full Evidence Package in Focus

Enhertu's Lung Cancer Results Put the Full Evidence Package in Focus

Editorial Team14 September 2026 · 4 min

Trodelvy's Regional Results Turn Attention to How Global Trials Are Read

Trodelvy's Regional Results Turn Attention to How Global Trials Are Read

Editorial Team13 September 2026 · 4 min

The Diabetes Association's Boycott Dispute Exposes the Value of Scientific Trust

The Diabetes Association's Boycott Dispute Exposes the Value of Scientific Trust

Editorial Team12 September 2026 · 4 min

Frazier's $1.1 Billion Raise Gives Biotech More Buying Power

Frazier's $1.1 Billion Raise Gives Biotech More Buying Power

Editorial Team11 September 2026 · 4 min

Biotech's Funding Recovery Needs a Second Test

Biotech's Funding Recovery Needs a Second Test

Editorial Team11 September 2026 · 4 min

Gene Therapy Funding Comes With a Delivery Test

Gene Therapy Funding Comes With a Delivery Test

Editorial Team9 September 2026 · 4 min

Obesity Investors Are Looking Beyond Appetite

Obesity Investors Are Looking Beyond Appetite

Editorial Team8 September 2026 · 4 min

Pelacarsen's Setback Tests a Bigger Assumption

Pelacarsen's Setback Tests a Bigger Assumption

Editorial Team7 September 2026 · 4 min

Biotech's Listing Route Is Changing

Biotech's Listing Route Is Changing

Editorial Team6 September 2026 · 4 min